CD47 and neoplasm: Previous studies have shown that targeting the CD47/SIRPα axis with anti-CD47 agents (including antibodies and SIRPα-Fc fusion proteins) promotes the phagocytosis of tumor cells by macrophages in vitro, and inhibits tumor growth in many human tumor xenograft models [7–12].